🧬 #ESMO26 | Abstract 4736O
OncoAlert🚨 #Podium2Screen Series

What did the phase III CA017-078 trial reveal about perioperative immunotherapy in muscle-invasive bladder cancer (MIBC)?

📊 Key results 🔹 Event-free survival: No statistically significant difference between perioperative nivolumab + gemcitabine/cisplatin (GC) and GC alone (HR 0.94; P = 0.67). 🔹 Pathologic complete response: 39.1% vs 29.6%, respectively; the difference was not statistically significant. 🔹 Overall survival: Data remained immature. 🔹 Safety: Grade ≥3 treatment-related adverse events occurred in 45.9% vs 49.5%.

🎤 Abstract 4736O 👨‍⚕️ Speaker: @AndreaNecchi 🇮🇹, Milan, Italy 🕐 Presentation: 13:40–13:50

@shilpaonc, @MattGalsky

Although the primary endpoints were not significantly different, these findings contribute to the ongoing discussion about optimizing perioperative treatment strategies for MIBC.

💬 How might future biomarker analyses, including ctDNA, help refine treatment selection?

Pinging Our Faculty
@DrChoueiri, @tompowles1, @apolo_andrea, @neerajaiims, @montypal, @Silke_Gillessen, @AOmlin, @brian_rini, @PGrivasMDPhD, @TiansterZhang, @amerseburger, @DrDanielHeng, @HHammersMD, @scocmem, @AndreaNecchi, @AmandaNizamMD, @drenriquegrande, @nataliagandur, @AlbigesL, @cdanicas, @declangmurphy, @seanmmcbride, @shilpaonc, @DrRanaMcKay, @scserendipity1, @DrYukselUrun, @ravikanesvaran, @BraunMDPhD, @EfstathiouEleni, @mzugman, @crisbergerot, @niklas_kluemper @Markuseckstein3